Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blinatumomab as Post-Allo-HSCT Maintenance in Pre B-cell ALL and B-cell NHL
NCT03114865Phase 2Active, not recruiting
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Sep 2017
- Primary completion
- Dec 2026
- Modality
- Antibody Conjugates, scFv Fragments, Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of blinatumomab in acute lymphoblastic leukemia (ALL) and B-cell non-Hodgkin lymphoma, sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoint: Overall Survival at 2 years. Started Sep 2017; status: active, not recruiting.
02
Drugs
blinatumomab
03
Conditions
acute lymphoblastic leukemia (ALL)B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT03114865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03114865.